Adverse Events Associated with Disease-Modifying Drugs for Multiple Sclerosis
Neurol 102:e208006, Ng, HS.,et al, 2024
Infection Risks Among Patients with Multiple Sclerosis Treated with Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
JAMA Neurol 77:184-191, Luna, G.,et al, 2020
Systematic Review: Efficacy and Safety of Medical Marijuana in Selected Neurologic Disorders
Neurol 82:1556-1563, Koppel, B.S.,et al, 2014
Carotid Plaque Hemorrhage on Magnetic Resonance Imaging Strongly Predicts Recurrent Ischemia and Stroke
Ann Neurol 73:774-784, Hosseini, A.,et al, 2013
Quantifying the Risks and Benefits of Natalizumab in Relapsing Multiple Sclerosis
Neurol 68:1524-1528, Dorsey,E.R.,et al, 2007
Multiple Ischemic Strokes Associated With Use of Recombinant Activated Factor VII
Arch Neurol 64:879-881, Libman,R.B.,et al, 2007
Patent Foramen Ovale Management for Secondary Stroke Prevention:State-of-the-Art Appraisal of Current Evidence
Stroke 55:236-247, Sposato,L.A.,et al, 2024
Dual Antiplatelet Treatment up to 72 Hours After Ischemic Stroke
NEJM 389:2413-2424, 2478, Gao,Y.et al, 2023
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Should Patients with Ischemic Stroke or Transient Ischemic Attack with Atrial Fibrillation and Microbleeds be Anticoagulated?
Stroke 48:3408-3412, Shoamanesh, A.,et al, 2017
Recurrence of ICH after Resumption of Anticoagulation with VK Antagonists
Neurol 82:1020-1026,1016, Poli, D.,et al, 2014
Resumption of Oral Anticoagulation After Warfarin-Associated Intracerebral Hemorrhage
Stroke 42:3661-3662, 3665, Steiner, T., 2011
Resumption of Oral Anticoagulation After Warfarin-Associated Intracereral Hemorrhage
Stroke 42:3663-3664, 3665, Schulman, S., 2011
Restarting Anticoagulation Therapy After Warfarin-Associated Intracerebral Hemorrhage
Arch Neuol 65:1313-1318, Claassen,D.O.,et al, 2008
Bleeding Risk Analysis in Stroke Imaging Before ThromboLysis (BRASIL): Pooled Analysis of T2*-Weighted Magnetic Resonance Imaging Data From 570 Patients
Storke 38:2738-2744, Fiehler,J.,et al, 2007
The Stroke-Thrombolytic Predictive Instrument: A Predictive Instrument for Intravenous Thrombolysis in Acute Ischemic Stroke
Stroke 37:2957-2962,2865, Kent,D.M.,et al, 2006
Can Multivariable Risk-Benefit Profiling Be Used to Select Treatment-Favorable Patients for Thrombolysis in Stroke in the 3- to 6-Hour Time Window?
Stroke 37:2963-2969, Kent,D.M.,et al, 2006
Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005
Emergent Use of Anticoagulation for Treatment of Patients with Ischemic Stroke
Stroke 33:856-861, Adams,H.P., 2002
Practice Advisory:The Use of Felbamate in the Treatment of Patients with Intractable Epilepsy, Report of the quality Standards Subcommittee of the AAN and the American Epilepsy Society
Neurol 52:1540-1545, French,J.,et al, 1999
Risks and Benefits of Screening for Intracranial Aneurysms in First-Degree Relatives of Patients with Sporadic Subarachnoid Hemorrhage
NEJM 341:1344-1350, The Magnetic Resonance Angiography in Relatives of, 1999